BioSpace News Archive

AbbVie, a research-based global biopharmaceutical company, announced a donation of $35 million to support COVID-19 relief efforts.

BioSyent Inc. announces that its Board of Directors has approved a grant of 129,125 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

ABM Respiratory care, a medical device company focused on developing novel integrated airway clearance and ventilation solutions, announced that it has received 510 clearance to market its innovative cough therapy system.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

SanBio Co., Ltd. hereby announces that SanBio has entered into a business alliance with Ocumension Limited.

Thermo Scientific iCAP PRO Series ICP-OES instruments capture a complete spectrum in a single measurement for high matrix samples

Mimetogen Pharmaceuticals Inc. (“Mimetogen”), a clinical-stage biopharmaceutical company focused on the development of tavilermide, a first-in-class nerve growth factor (NGF) mimetic for the treatment of dry eye disease, today announced that it completed enrollment of its 600-patient MIM-728 Phase 3 clinical trial for tavilermide ophthalmic solution.

All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular and neurovascular markets, announced it has closed an additional $8.8 million in Series A financing, bringing the total capital raised to date to more than $20 million.

Multiple highly potent, neutralizing antibodies already identified from convalesced patients